Novartis AG (NVS) Q3 2026 Earnings Call Transcript

Impact · against what's priced in

Novartis (NVS) is likely to see a positive price adjustment following an upgrade to its full-year 2026 guidance. The revision is driven by strong Q3 sales growth and core margin expansion.

NVS+0.60

No priced-in read yet

In context

The company upgraded its full-year 2026 guidance after delivering Q3 sales growth and core margin expansion, which typically triggers upward revisions to EPS estimates.

Read from the article alone

Actual

• NVS▲600%
• earnings
• guidance
• healthcare
• pharmaceuticals
• sales growth
• switzerland

Top 1 mover · tap to explore